[1]李　鹏,常玉喜,王慧娟,等.程序性死亡受体配体1和E3泛素连接酶Cbl-b在非小细胞肺癌组织中的表达及临床意义[J].新乡医学院学报,2019,36(1):045-49.[doi:10.7683/xxyxyxb.2019.01.009]
　LI Peng,CHANG Yu-xi,WANG Hui-juan,et al.Clinical significance of the expression of programmed death receptor ligand 1 and E3 ubiquitin ligase Cbl-b in non-small cell lung cancer tissues[J].Journal of Xinxiang Medical University,2019,36(1):045-49.[doi:10.7683/xxyxyxb.2019.01.009]
点击复制

程序性死亡受体配体1和E3泛素连接酶Cbl-b在非小细胞肺癌组织中的表达及临床意义
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
36
期数:
2019年1
页码:
045-49
栏目:
临床研究
出版日期:
2019-01-05

文章信息/Info

Title:
Clinical significance of the expression of programmed death receptor ligand 1 and E3 ubiquitin ligase Cbl-b in non-small cell lung cancer tissues
作者:
李　鹏1; 常玉喜2; 王慧娟1; 张国伟1; 闫相涛1; 张米娜1; 杨金坡1; 张晓娟1; 马　杰2; 马智勇1
（1.河南省肿瘤医院　郑州大学附属肿瘤医院呼吸内科，河南　郑州　450008；2.河南省肿瘤医院　郑州大学附属肿瘤医院分子病理科，河南　郑州　450008）
Author(s):
LI Peng1; CHANG Yu-xi2; WANG Hui-juan1; ZHANG Guo-wei1; YAN Xiang-tao1; ZHANG Mi-na1; YANG Jin-po1; ZHANG Xiao-juan1; MA Jie2; MA Zhi-yong1
（1.Department of Respiratory Medicine，Henan Tumor Hospital，Tumor Hospital Affiliated to Zhengzhou University，Zhengzhou 450008，Henan Province，China；2.Department of Molecular Pathology，Henan Tumor Hospital，Tumor Hospital Affiliated to Zhengzhou University，Zhengzhou 450008，Henan Province，China）
关键词:
非小细胞肺癌; 程序性死亡受体1; 程序性死亡受体配体1; E3泛素连接酶; Cbl-b
Keywords:
non-small cell lung carcer; programmed death receptor ligand 1; E3 ubiquitin ligase; Cbl-b
分类号:
R734.2
DOI:
10.7683/xxyxyxb.2019.01.009
文献标志码:
A
摘要:
目的　探讨程序性死亡受体配体1（PD-L1）和E3泛素连接酶Cbl-b蛋白在非小细胞肺癌（NSCLC）组织中的表达及临床意义。方法　选取2004年7月至2009年6月河南省肿瘤医院保存的NSCLC组织标本及癌旁组织标本各165例，制作组织切片。采用免疫组织化学方法检测NSCLC组织中PD-L1和Cbl-b蛋白表达，并分析NSCLC组织中PD-L1与Cbl-b蛋白表达的关系，以及PD-L1、Cbl-b蛋白表达与NSCLC患者预后的关系。结果　NSCLC组织中PD-L1和Cbl-b阳性表达率分别为72.73%（120/165）、38.79%（64/165），癌旁组织中PD-L1和Cbl-b阳性表达率均为7.88%（13/165）；NSCLC组织中PD-L1和Cbl-b阳性表达率显著高于癌旁组织（χ2=5.292、3.076，P<0.05）。PD-L1蛋白表达与NSCLC患者的年龄、性别、肿瘤分期、肿瘤直径、阳性淋巴结数、病理类型及病理分级无关（P>0.05）。Cbl-b蛋白表达与NSCLC患者的性别及肿瘤病理类型有关（P<0.05），与患者的年龄、肿瘤分期、肿瘤直径、阳性淋巴结数及病理分级无关（P>0.05）。NSCLC组织中PD-L1和Cbl-b蛋白表达呈直线关系（R2=0.075，P<0.01），其模型为y=21.464 93+0.532 65x。PD-L1蛋白高表达和低表达NSCLC患者的中位总生存期（OS）分别为45.0、52.0个月，PD-L1蛋白高表达与低表达NSCLC患者的中位OS比较差异无统计学意义（P>0.05）。75例鳞状细胞癌患者中，PD-L1 蛋白高表达和低表达患者的中位OS分别为45.0、81.0个月，PD-L1蛋白高表达的鳞状细胞癌患者的中位OS显著短于低表达患者（P<0.05）。90例腺癌患者中，PD-L1高表达和低表达患者的中位OS分别为50.0、39.0个月，PD-L1高表达与低表达腺癌患者的中位OS比较差异无统计学意义（P>0.05）。Cbl-b蛋白高表达和低表达NSCLC患者的中位OS分别为39.0、54.5个月，Cbl-b蛋白高表达患者的中位OS显著短于低表达患者（P<0.05）。结论　Cbl-b和PD-L1蛋白在NSCLC组织中均呈高表达。PD-L1与Cbl-b蛋白表达呈直线相关。Cbl-b蛋白表达情况与NSCLC患者的性别、病理类型及OS有关。PD-L1蛋白表达与鳞状细胞癌患者的生存期有相关性，但PD-L1蛋白表达与腺癌患者的生存期无相关性。
Abstract:
Objective　To investigate the clinical significance of the expression of programmed death receptor ligand 1（PD-L1） and E3 ubiquitin ligase Cbl-b in non-small cell lung cancer （NSCLC） tissues.Methods　A total of 165 NSCLC tissue specimens and 165 paracancerous tissue specimens were collected in Henan Tumor Hospital from July 2004 to June 2009 and then were made into tissue slice.The expression of PD-L1 and Cbl-b in NSCLC tissues was detected by immunohistochemistry.The relationship between the expression of PD-L1 and Cbl-b protein in NSCLC tissues was analyzed.The relationship between the expression of PD-L1，Cbl-b protein and the prognosis of NSCLC patients was analyzed.Results　The positive rate of PD-L1 and Cbl-b in NSCLC tissues was 72.73% （120/165） and 38.79% （64/165），respectively.The positive rate of PD-L1 and Cbl-b in paracancerous tissues was 7.88% （13/165）.The positive rates of PD-L1 and Cbl-b in NSCLC tissues were significantly higher than those in paracancerous tissues （χ2=5.292，3.076；P<0.05）.The expression of PD-L1 protein was not correlated with the age，sex，tumor stage，tumor diameter，the number of positive lymph nodes，pathological type and pathological grade of NSCLC patients （P>0.05）.The expression of Cbl-b protein was correlated with the sex of patients and pathological type of NSCLC （P<0.05），but it was not correlated with the age，tumor stage，tumor diameter，the number of positive lymph nodes and pathological grade of NSCLC（P>0.05）.The expression of PD-L1 and Cbl-b protein in NSCLC tissues showed a linear relationship （R2=0.075；P<0.01），and the model was y=21.464 93+0.532 65x.The median overall survival （OS） of the patients with high and low expression of PD-L1 protein was 45.0 and 52.0 months，respectively.There was no significant difference in the median OS between the NSCLC patients with high and low expression of PD-L1 protein （P>0.05）.Among the 75 patients with squamous cell carcinoma，the median OS of the patients with high and low expression of PD-L1 protein was 45.0 and 81.0 months，respectively；the median OS of the patients with high expression of PD-L1 protein was significantly shorter than that in the patients with low expression of PD-L1 protein （P<0.05）.Among the 90 patients with adenocarcinoma，the median OS of the patients with high and low expression of PD-L1 protein was 50.0 and 39.0 months，respectively；there was no significant difference in the median OS between the adenocarcinoma patients with high and low expression of PD-L1 protein （P>0.05）.The median OS of the patients with high and low expression of Cbl-b protein was 39.0 and 54.5 months，respectively；the median OS of the patients with high expression of Cbl-b protein was significantly shorter than that in the patients with low expression of Cbl-b protein （P<0.05）.Conclusion　The expression of Cbl-b and PD-L1 protein are high in NSCLC tissues.The expression of PD-L1 and Cbl-b protein in NSCLC tissues shows a linear relationship.The expression of Cbl-b protein is related to the sex，pathological type and OS of NSCLC patients.The expression of PD-L1 protein is correlated with the survival time of the patients with squamous cell carcinoma，but there was no correlation between the expression of PD-L1 protein and the survival time of the patients with adenocarcinoma.

参考文献/References:

［1］　OKAZAKI T，HONJO T.PD-1 and PD-1 ligands：from discovery to clinical application［J］.Int Immunol，2007，19（7）：813-824.
［2］　FREEMAN G J，LONG A J，IWAI Y，et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation［J］.J Exp Med，2000，192（7）：1027-1034.
［3］　ZHOU G W，XIONG Y，CHEN S，et al.Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer：a meta-analysis of randomized clinical trials［J］.Medicine （Baltimore），2016，95（35）：e4611.
［4］　PAOLINO M，THIEN C B，GRUBER T，et al.Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions［J］.J Immunol，2011，186（4）：2138-2147.
［5］　TRAVIS W D，HARRIS C.Pathology and genetics of tumours of the lung，pleura，thymus and heart［M］.Lyon：IARC Press，2004：53-58.
［6］　GREENE F L.The American Joint Committee on Cancer：updating the strategies in cancer staging［J］.Bull Am Coll Surg，2002，87（7）：13-15.
［7］　SUN Z，AUBRY M C，DESCHAMPS C，et al.Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer：an analysis of 5018 hospital- and 712 population-based cases［J］.J Thorac Cardiovasc Surg，2006，131（5）：1014-1020.
［8］　AMERATUNGA M，ASADI K，LIN X，et al.PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected NSCLC［J］.PLoS One，2016，11（4）：e0153954.
［9］　LEPIKHOVA T，KARHEMO P R，LOUHIMO R，et al.Drug sensitivity screening and genomic characterization of 45 HPV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy［J］.Mol Cancer Ther，2018，17（9）：2060-2071.
［10］　ROACH C，ZHANG N，CORIGLIANO E，et al.Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer［J］.Appl Immunohistochem Mol Morphol，2016，24（6）：392-397.
［11］　GANDHI L，RODRIGUEZ-ABREU D，GADGEEL S，et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer［J］.N Engl J Med，2018，378（22）：2078-2092.
［12］　LITTMAN D R.Releasing the brakes on cancer immunotherapy［J］.Cell，2015，162（6）：1186-1190.
［13］　MITCHELL P L，JOHN T.Lung cancer in 2016：immunotherapy comes of age［J］.Lancet Respir Med，2016，4（12）：947-949.
［14］　STERLACCI W，FIEGL M，DROESER R A，et al.Expression of PD-L1 identifies a subgroup of more aggressive non-small cell carcinomas of the lung［J］.Pathobiology，2016，83（5）：267-275.
［15］　SUN J M，ZHOU W，CHOI Y L，et al.Prognostic significance of PD-L1 in patients with non-small cell lung cancer：a large cohort study of surgically resected cases［J］.J Thorac Oncol，2016，11（7）：1003-1011.

相似文献/References:

[1]张开普.介入治疗局部晚期非小细胞肺癌42例[J].新乡医学院学报,2002,19(05):421.
[2]牛红蕊,袁 亮,吴随群.羟基喜树碱联合顺铂和足叶乙甙治疗中晚期非小细胞肺癌39例[J].新乡医学院学报,2002,19(05):419.
[3]赫鸿昌.异长春花碱联合顺铂治疗晚期非小细胞肺癌l7例[J].新乡医学院学报,2003,20(02):126.
[4]赫鸿昌.异长春花碱联合顺铂治疗晚期非小细胞肺癌17 例[J].新乡医学院学报,2003,20(02):126.
[5]张海君,闫卫东,邝先奎.目的从伦理学的角度来思考基因歧视产生的原因和所引起的危害，并寻求对策。方法查阅并分析近1O年的文献。结果导致基因歧视产生的理论观点是不正确的，这种现象对人类有极大的危害，人们可以通过对隐私权的保护来避免或减轻它对人类的伤害。结论 基因歧视是不公正也是不[J].新乡医学院学报,2003,20(06):428.
[6]杨廷桐,李秀杰,武俊芳,等.端粒酶反转录酶活化与p53金属蛋白酶-9表达对非小细胞肺癌发生的影响[J].新乡医学院学报,2007,24(05):000.
[7]杨廷桐,武俊芳,李秀杰,等.非小细胞肺癌中p14ARF和mtp53蛋白表达与临床病理参数的关系[J].新乡医学院学报,2008,25(04):336.
[8]姬明丽,千智斌,徐自超.p53蛋白与非小细胞肺癌多药耐药性的关系[J].新乡医学院学报,2008,25(01):013.
[9]孙秀威,陈玉玲,黄鹏.非小细胞肺癌中核糖核苷酸还原酶亚单位M1 表达及其与吉西他滨化学治疗敏感性相关研究[J].新乡医学院学报,2011,28(02):157.
[10]郑翠侠,韩兵,周翔,等.非小细胞肺癌中表皮生长因子受体基因突变的筛查[J].新乡医学院学报,2011,28(02):190.

更新日期/Last Update: 2019-01-05